Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IMC-1121B

A drug that binds to the protein vascular endothelial growth factor (VEGF) to help keep new blood vessels from forming and is used to treat different types of cancer. It is used alone or with other drugs to treat certain types of non-small cell lung cancer, hepatocellular carcinoma (a type of liver cancer), colorectal cancer, stomach cancer, and gastroesophageal junction cancer. It is also being studied in the treatment of other types of cancer. IMC-1121B may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody. Also called anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Cyramza, and ramucirumab.
More Information
Search NCI's Dictionary of Cancer Terms